Events

Kinetics expert, Dr. Thomas Schubert will present how using the model system P38 to demonstrate a screening application of waveRAPID, using a library of kinase inhibitors. With waveRAPID®, 2bind is now able to efficiently screen 1000s of molecules for binding kinetics and affinity.

Being able to test newly synthesized molecules is a pivotal part of early-stage drug discovery, with the data from assays driving decisions on the next molecules to be developed. The waveRAPID technology enables testing of full kinetic parameters for up to 400 compound fragments unattended in a 24-hour period.

Trevor Askwith presents how Domainex is using waveRAPID to accelerate the analogue expansion to support our fragment and virtual screening hit ID platforms.

Kinetics in hours instead of days

Introducing the waveRAPID^®, the new way of measuring kinetics to boost throughput. Instead of relying a titration series in conventional kinetics, waveRAPID injects a single concentration, pulsing the sample over the sensing surface at increasing durations. From a single well, kinetics can be derived: the on-rate, off-rate, affinity and R_max. With no need for serial dilutions or DMSO corrections, set-up time is significantly reduced, runs are faster, and wells are freed up to run more samples.

We have put together a fantastic line-up of scientists from both industry in academia to share their experiences with the waveRAPID.

Very excited to be part of the SLASDigital 2021 Conference again this year. Don't miss the chance to visit our virtual booth, interact with our team for a sneak peak at waveRAPID^® and keep an eye on the New Product Award announcement on January 27th!

In this seminar we want to get your feedback on our brand new product – waveRAPID^® – which stands for Rapid Analyte Pulses of Increasing Duration. With this new way of measuring kinetics, short pulses of increasing duration – but same concentration – are used to probe biomolecular interactions. Be ready to obtain a complete kinetic readout (including on- and off-rates) from a single well and WAVE goodbye to serial dilutions and DMSO corrections.

Discover the benefits of early stage kinetic characterization to complement and validate binding affinity in crude reaction mixtures, biofluids (serum and plasma) and other matrixes with Dr. Michael Goldflam (Pepscan) and Dr. Fabio Andres (Creoptix).

Discover the benefits of early stage kinetic characterization with our WAVEsystem at PEGSVirtual 2020. Expect to see high-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.

Discover the WAVEsystem in less than 30 minutes with out Let's Talk Kinetics! Virtual Seminar Series. Get acquainted with our GCI technology and the applications of our WAVEsystem for small molecule research and binding kinetics onto membrane proteins.

In this webinar, Dr. Shawn Owen (University of Utah) discusses advanced characterization techniques to assess antibody-drug conjugates (ADCs), while Dr. Ellen Lee (Creoptix), goes deep into the biophysical characterization of biologics using the Creoptix WAVEsystem.

Experience a new level of performance and flexibility in drug discovery with our CTO and Founder Kaspar Cottier at the Hellen Diller Auditorium @UCSF, Mission Bay in San Francisco. In a nutshell, sensorgrams galore!